407 related articles for article (PubMed ID: 32039250)
1. The Potential of Mesenchymal Stem Cells to Treat Systemic Inflammation in Horses.
MacDonald ES; Barrett JG
Front Vet Sci; 2019; 6():507. PubMed ID: 32039250
[TBL] [Abstract][Full Text] [Related]
2. Effect of inflammatory environment on equine bone marrow derived mesenchymal stem cells immunogenicity and immunomodulatory properties.
Barrachina L; Remacha AR; Romero A; Vázquez FJ; Albareda J; Prades M; Ranera B; Zaragoza P; Martín-Burriel I; Rodellar C
Vet Immunol Immunopathol; 2016 Mar; 171():57-65. PubMed ID: 26964718
[TBL] [Abstract][Full Text] [Related]
3. Multiple intravenous injections of allogeneic equine mesenchymal stem cells do not induce a systemic inflammatory response but do alter lymphocyte subsets in healthy horses.
Kol A; Wood JA; Carrade Holt DD; Gillette JA; Bohannon-Worsley LK; Puchalski SM; Walker NJ; Clark KC; Watson JL; Borjesson DL
Stem Cell Res Ther; 2015 Apr; 6(1):73. PubMed ID: 25888916
[TBL] [Abstract][Full Text] [Related]
4. The immunomodulatory function of equine MSCs is enhanced by priming through an inflammatory microenvironment or TLR3 ligand.
Cassano JM; Schnabel LV; Goodale MB; Fortier LA
Vet Immunol Immunopathol; 2018 Jan; 195():33-39. PubMed ID: 29249315
[TBL] [Abstract][Full Text] [Related]
5. Canine and Equine Mesenchymal Stem Cells Grown in Serum Free Media Have Altered Immunophenotype.
Clark KC; Kol A; Shahbenderian S; Granick JL; Walker NJ; Borjesson DL
Stem Cell Rev Rep; 2016 Apr; 12(2):245-56. PubMed ID: 26638159
[TBL] [Abstract][Full Text] [Related]
6. The systemic cellular immune response against allogeneic mesenchymal stem cells is influenced by inflammation, differentiation and MHC compatibility:
Cequier A; Vázquez FJ; Vitoria A; Bernad E; Fuente S; Serrano MB; Zaragoza MP; Romero A; Rodellar C; Barrachina L
Front Vet Sci; 2024; 11():1391872. PubMed ID: 38957800
[TBL] [Abstract][Full Text] [Related]
7. Equine mesenchymal stem cells inhibit T cell proliferation through different mechanisms depending on tissue source.
Carrade Holt DD; Wood JA; Granick JL; Walker NJ; Clark KC; Borjesson DL
Stem Cells Dev; 2014 Jun; 23(11):1258-65. PubMed ID: 24438346
[TBL] [Abstract][Full Text] [Related]
8. Priming Equine Bone Marrow-Derived Mesenchymal Stem Cells with Proinflammatory Cytokines: Implications in Immunomodulation-Immunogenicity Balance, Cell Viability, and Differentiation Potential.
Barrachina L; Remacha AR; Romero A; Vázquez FJ; Albareda J; Prades M; Gosálvez J; Roy R; Zaragoza P; Martín-Burriel I; Rodellar C
Stem Cells Dev; 2017 Jan; 26(1):15-24. PubMed ID: 27712399
[TBL] [Abstract][Full Text] [Related]
9. Allo-antibody production after intraarticular administration of mesenchymal stem cells (MSCs) in an equine osteoarthritis model: effect of repeated administration, MSC inflammatory stimulation, and equine leukocyte antigen (ELA) compatibility.
Barrachina L; Cequier A; Romero A; Vitoria A; Zaragoza P; Vázquez FJ; Rodellar C
Stem Cell Res Ther; 2020 Feb; 11(1):52. PubMed ID: 32028995
[TBL] [Abstract][Full Text] [Related]
10. The immunomodulation-immunogenicity balance of equine Mesenchymal Stem Cells (MSCs) is differentially affected by the immune cell response depending on inflammatory licensing and major histocompatibility complex (MHC) compatibility.
Cequier A; Vázquez FJ; Romero A; Vitoria A; Bernad E; García-Martínez M; Gascón I; Barrachina L; Rodellar C
Front Vet Sci; 2022; 9():957153. PubMed ID: 36337202
[TBL] [Abstract][Full Text] [Related]
11. Preliminary evaluation of safety and migration of immune activated mesenchymal stromal cells administered by subconjunctival injection for equine recurrent uveitis.
Cassano JM; Leonard BC; Martins BC; Vapniarsky N; Morgan JT; Dow SW; Wotman KL; Pezzanite LM
Front Vet Sci; 2023; 10():1293199. PubMed ID: 38162475
[TBL] [Abstract][Full Text] [Related]
12. Inflammatory response to the administration of mesenchymal stem cells in an equine experimental model: effect of autologous, and single and repeat doses of pooled allogeneic cells in healthy joints.
Ardanaz N; Vázquez FJ; Romero A; Remacha AR; Barrachina L; Sanz A; Ranera B; Vitoria A; Albareda J; Prades M; Zaragoza P; Martín-Burriel I; Rodellar C
BMC Vet Res; 2016 Mar; 12():65. PubMed ID: 27029614
[TBL] [Abstract][Full Text] [Related]
13. Equine allogeneic umbilical cord blood derived mesenchymal stromal cells reduce synovial fluid nucleated cell count and induce mild self-limiting inflammation when evaluated in an lipopolysaccharide induced synovitis model.
Williams LB; Koenig JB; Black B; Gibson TW; Sharif S; Koch TG
Equine Vet J; 2016 Sep; 48(5):619-25. PubMed ID: 26114736
[TBL] [Abstract][Full Text] [Related]
14. Mesenchymal stem cells for treatment of musculoskeletal disease in horses: Relative merits of allogeneic versus autologous stem cells.
Colbath AC; Dow SW; McIlwraith CW; Goodrich LR
Equine Vet J; 2020 Sep; 52(5):654-663. PubMed ID: 31971273
[TBL] [Abstract][Full Text] [Related]
15. The Usefulness of Mesenchymal Stem Cells beyond the Musculoskeletal System in Horses.
Cequier A; Sanz C; Rodellar C; Barrachina L
Animals (Basel); 2021 Mar; 11(4):. PubMed ID: 33805967
[TBL] [Abstract][Full Text] [Related]
16. Autologous bone marrow mesenchymal stromal cells for regeneration of injured equine ligaments and tendons: a clinical report.
Renzi S; Riccò S; Dotti S; Sesso L; Grolli S; Cornali M; Carlin S; Patruno M; Cinotti S; Ferrari M
Res Vet Sci; 2013 Aug; 95(1):272-7. PubMed ID: 23419936
[TBL] [Abstract][Full Text] [Related]
17. Effect of allogeneic platelet lysate on equine bone marrow derived mesenchymal stem cell characteristics, including immunogenic and immunomodulatory gene expression profile.
Yaneselli K; Barrachina L; Remacha AR; Algorta A; Vitoria A; Cequier A; Romero A; Vázquez FJ; Maisonnave J; Rodellar C
Vet Immunol Immunopathol; 2019 Nov; 217():109944. PubMed ID: 31563725
[TBL] [Abstract][Full Text] [Related]
18. Equine allogeneic bone marrow-derived mesenchymal stromal cells elicit antibody responses in vivo.
Pezzanite LM; Fortier LA; Antczak DF; Cassano JM; Brosnahan MM; Miller D; Schnabel LV
Stem Cell Res Ther; 2015 Apr; 6(1):54. PubMed ID: 25889095
[TBL] [Abstract][Full Text] [Related]
19. Inflammatory licensed equine MSCs are chondroprotective and exhibit enhanced immunomodulation in an inflammatory environment.
Cassano JM; Schnabel LV; Goodale MB; Fortier LA
Stem Cell Res Ther; 2018 Apr; 9(1):82. PubMed ID: 29615127
[TBL] [Abstract][Full Text] [Related]
20. Assessment of effectiveness and safety of repeat administration of proinflammatory primed allogeneic mesenchymal stem cells in an equine model of chemically induced osteoarthritis.
Barrachina L; Remacha AR; Romero A; Vitoria A; Albareda J; Prades M; Roca M; Zaragoza P; Vázquez FJ; Rodellar C
BMC Vet Res; 2018 Aug; 14(1):241. PubMed ID: 30119668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
